Urinary excretion of endothelin-1 (ET-1), transforming growth factor- 1 (TGF- 1) and vascular endothelial growth factor (VEGF165) in paediatric chronic kidney diseases: results of the ESCAPE trial.

Urinary excretion of endothelin-1 (ET-1), transforming growth factor- 1 (TGF- 1) and vascular endothelial growth factor (VEGF165) in paediatric chronic kidney diseases: results of the ESCAPE trial. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Urinary excretion of endothelin-1 (ET-1), transforming growth factor- 1 (TGF- 1) and vascular endothelial growth factor (VEGF165) in paediatric chronic kidney diseases: results of the ESCAPE trial. Abstract Text:

Ryszard Grenda,Elke ,Mieczyslaw Litwin,Roman Janas,Joanna Sladowska,Klaus Arbeiter,Ulla Berg,Alberto Caldas-Afonso,Michel Fischbach,Otto Mehls,Peter Sallay,Franz Schaefer, ,

The severity and dynamics of renal tissue damage in chronic kidney disease (CKD) may be reflected by the urinary excretion of vasoactive and growth factors released by the damaged kidney. Urinary excretion of ET-1, TGF-beta1 and VEGF(165) was evaluated in 303 children with CKD stage II-IV (GFR 48 +/- 22 ml/min/1.73 m(2)) and 81 age-matched healthy controls. Major renal disease groups were hypo-/dysplastic kidney disease (N = 183), obstructive uropathies (N = 47), glomerulopathies (N = 34), nephronophthisis (N = 19) and polycystic kidney disease (N = 20). RESULTS: The mean urinary excretion rates of each of the three putative biomarkers were significantly elevated in CKD patients compared to controls: 965 +/- 2042 vs 216 +/- 335 fmol/g creatinine for ET-1; 252 +/- 338 vs 155 +/- 158 ng/g for VEGF; 31.6 +/- 37.0 vs 10.9 +/- 9.8 ng/g for TGF-beta1 (each P < 0.0001). The excretion of ET-1 and TGF-beta1 was highest in patients with obstructive uropathies. In the patients, ET-1, TGF-beta1 and VEGF excretion rates were inversely correlated with age (r = -0.22, -0.32 and -0.17, all P < 0.005) and renal function (r = -0.21, -0.13 and -0.15; P < 0.001; < 0.05; < 0.01; respectively) VEGF and TGF-beta1 excretion rates were positively correlated both in patients and controls. CONCLUSIONS: Children with CKD exhibit significantly elevated urinary excretion of ET-1, TGF-beta1 and VEGF(165) in comparison to healthy children. Urinary excretion of these biomarkers was most enhanced in patients with obstructive uropathies. A positive correlation between urinary TGF-beta1 and VEGF(165) excretion, shown both in patients and healthy controls, indicates an interdependent nature of their generation.

Urinary excretion of endothelin-1 (ET-1), transforming growth factor- 1 (TGF- 1) and vascular endothelial growth factor (VEGF165) in paediatric chronic kidney diseases: results of the ESCAPE trial. Publishing Authors By Initials

R Grenda,E ,M Litwin,R Janas,J Sladowska,K Arbeiter,U Berg,A Caldas-Afonso,M Fischbach,O Mehls,P Sallay,F Schaefer, ,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Urinary excretion of endothelin-1 (ET-1), transforming growth factor- 1 (TGF- 1) and vascular endothelial growth factor (VEGF165) in paediatric chronic kidney diseases: results of the ESCAPE trial. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Nephrology, dialysis, transplantation : official p

VOLUME: 22

Page Numbers: 3487-94

Journal Abbreviation: Nephrol. Dial. Transplant.

ISSN: 0931-0509

DAY: 26

MONTH: 09

YEAR: 2007

Urinary excretion of endothelin-1 (ET-1), transforming growth factor- 1 (TGF- 1) and vascular endothelial growth factor (VEGF165) in paediatric chronic kidney diseases: results of the ESCAPE trial. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8706402

Urinary excretion of endothelin-1 (ET-1), transforming growth factor- 1 (TGF- 1) and vascular endothelial growth factor (VEGF165) in paediatric chronic kidney diseases: results of the ESCAPE trial. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Urinary excretion of endothelin-1 (ET-1), transforming growth factor- 1 (TGF- 1) and vascular endothelial growth factor (VEGF165) in paediatric chronic kidney diseases: results of the ESCAPE trial. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Urinary excretion of endothelin-1 (ET-1), transforming growth factor- 1 (TGF- 1) and vascular endothelial growth factor (VEGF165) in paediatric chronic kidney diseases: results of the ESCAPE trial.

AFFILIATION: Department of Nephrology, Kidney Transplantation and Hypertension, The Children's Memorial Health Institute, Al. Dzieci Polskich 20, 04-730 Warsaw, Poland. r.grenda@czd.pl.

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Nephrol Dial Transplant

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Urinary excretion of endothelin-1 ET-1, transforming growth factor- 1 TGF- 1 and vascular endothelial growth factor VEGF165 in paediatric chronic kidney diseases: results of the ESCAPE trial Related Publications

• A pilot study of telephone care management and structured disease self-management groups for chronic depression.
• A primer on iron therapy.
• An approach to the treatment of recurring polyarthralgia after jejunoileal bypass.
• Blind trials evaluating in vitro infectivity of Cryptosporidium oocysts using cell culture immunofluorescence.
• Cell culture models of the air-blood barrier for the evaluation of aerosol medicines.
• Changes in mouse circulating leukocyte numbers in C57BL/6 mice immunosuppressed with dexamethasone for Cryptosporidium parvum oocyst production.
• Clinical genetics in pediatric physical therapy practice? The future.
• Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome.
• Coupled cluster investigation on the low-lying electronic states of CuCN and CuNC and the ground state barrier to isomerization.
• Creation of a Correction Factor via Allometry to Eliminate Body Mass Influence on the Army's Physical Fitness Test: 1394: Board #157 May 30 11:00 AM - 12:30 PM.
• Decorin-mediated regulation of fibrillin-1 in the kidney involves the insulin-like growth factor-I receptor and Mammalian target of rapamycin.
• Determinants of influenza and pneumococcal vaccination in patients with chronic lung diseases.
• Drug related problems with Antiparkinsonian agents: consumer Internet reports versus published data.
• Effect of long- or short-term feeding of alpha-tocopheryl acetate to Holstein and crossbred beef steers on performance, carcass characteristics, and beef color stability.
• Effects of different doses of atorvastatin on human apolipoprotein B-100, B-48, and A-I metabolism.
• Effects of microsolvation on the adenine-uracil base pair and its radical anion: adenine-uracil mono- and dihydrates.
• Effects of retrospective quality control on pressure-flow data with computer-based urodynamic systems from men with benign prostatic hyperplasia.
• Electron attachment induced proton transfer in a DNA nucleoside pair: 2'-deoxyguanosine-2'-deoxycytidine.
• Functional eicosanoid test and typing (FET) in acetylsalicylic acid intolerant patients with urticaria.
• Hepatitis B virus genotypes in Europe.
• Hydrogen-atom abstraction from the adenine-uracil base pair.
• Investigation of Arterial Waves using Phase Averaging.
• Leukocytes induce epithelial to mesenchymal transition after unilateral ureteral obstruction in neonatal mice.
• Low-lying quartet electronic states of nitrogen dioxide.
• LpA-I, LpA-I:A-II HDL and CHD-risk: The Framingham Offspring Study and the Veterans Affairs HDL Intervention Trial.
• Methylprednisolone acetate immune suppression produces differing effects on Cryptosporidium muris oocyst production depending on when administered.
• Sliding multislice MRI for abdominal staging of rectal gastrointestinal stromal tumours.
• State of the art 3D MR-cholangiopancreatography for tumor detection.
• Unsaturated trinuclear osmium carbonyls: comparison with their iron analogues.
• Urinary excretion of endothelin-1 (ET-1), transforming growth factor- 1 (TGF- 1) and vascular endothelial growth factor (VEGF165) in paediatric chronic kidney diseases: results of the ESCAPE trial.